Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Clinical trial NCT05348577 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05348577
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Prostate Cancer

Start date: 2022-03-25
Primary completion: 2026-03-04
Enrollment: 1035

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.